Fig. 1From: Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to malesForest plots comparing relapse free survival (RFS) and overall survival (OS) for ipilimumab 3Â mg/kg versus high dose interferon-alfaBack to article page